Endobronchial Ultrasound Guided Transbronchial Needle Aspiration (EBUS-TBNA) for Mediastinal Re-staging of Non-small Cell Lung Cancer(NSCLC)

Endobronchial Ultrasound Guided Transbronchial Needle Aspiration for the Mediastinal Re-staging After Induction Therapy in Non-small Cell Lung Cancer. A Prospective Study

Status

Withdrawn

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00859742

Enrollment

Registered

2009-03-11

Start date

2009-03-31

Completion date

2010-08-31

Last updated

2018-04-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non Small Cell Lung Cancer

Brief summary

The aim of this study is to determine the diagnostic values of EBUS-TBNA in the mediastinal re-staging after induction treatment in patients with non-small cell lung cancer. Primary objective: 1\. To determine the sensitivity, specificity, positive predictive value, negative predictive value and the accuracy of EBUS-TBNA in the detection of mediastinal metastasis in mediastinal re-staging after induction treatment. Secondary objectives: 1. To compare the diagnostic values of EBUS-TBNA and integrated PET/CT in mediastinal re-staging 2. To evaluate the changes of ultrasonographic features of mediastinal lymph nodes after induction therapy 3. To determine procedure related complications

Interventions

PROCEDUREEBUS-TBNA, integrated PET/CT

EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

DIAGNOSTIC

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically proven non-small cell lung cancer * Patients who have initially histologically proven N2 disease (Stage IIIA) * Patients who underwent induction treatment (chemotherapy or chemoradiation therapy) and are considred for surgery * Written informed consent

Exclusion criteria

* Contraindications for bronchoscopy * Medically inoperable patients * Patients who are found to have M1 disease, inoperable T4 disease or supraclavicular metastasis after induction treatment

Design outcomes

Primary

Measure	Time frame
The diagnostic values of EBUS-TBNA in the mediastinal re-staging after induction treatment in non-small cell lung cancer.	1.5 years

Secondary

Measure	Time frame
The diagnostic values of integrated PET/CT in the mediastinal re-staging after induction treatment in non-small cell lung cancer	1.5 years
The changes of ultrasonographic features of mediastinal lymph nodes after induction therapy	1.5 years

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026